Megace® ES

Par Pharmaceutical Companies, Inc. (USA)

Drug designed to stimulate appetite for “treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS)”
“Utilizes Elan’s NanoCrystal technology delivery system to improve the rate of dissolution and bioavailability of the original megesterol acetate oral suspension”
“NanoCrystal particles are small particles of drug substance, typically less than 1000 nanometers (nm) in diameter, which are produced by milling the drug substance using a proprietary, wet-milling technique. The NanoCrystal particles of the drug are stabilized against agglomeration by surface adsorption of selected GRAS (Generally Regarded As Safe) stabilizers. The result is an aqueous dispersion of the drug substance that behaves like a solution – a NanoCrystal colloidal dispersion, which can be processed into finished dosage forms for all routes of administration.”
Approved by the FDA in July 2004